Dashboard
Manage Tickers

ZLABZai Lab Ltd

Nasdaq zailaboratory.com


$ 17.78 $ -0.41 (-2.25 %)    

Friday, 31-May-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.01 (-0 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.59 (0.88 %)
TLT $ 91.26 $ 0.69 (0.77 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 17.78
$ 18.58
$ 0.00 x 0
$ 0.00 x 0
$ 17.76 - $ 19.06
$ 13.48 - $ 37.92
1,628,377
na
17.3B
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

zai-lab-has-dosed-the-first-patient-in-the-phase-2-trial-of-zl-1102-for-chronic-plaque-psoriasis
Zai Lab Has Dosed The First Patient In The...
05/22/2024 11:34:45

This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai...

Core News & Articles
Zai Lab And Innoviva Specialty Therapeutic...
05/20/2024 04:40:14

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, ...

reported-sunday-zai-lab-received-approval--of-augtyro-repotrectinib-for-patients-with-ros1-positive-nsclc-by-chinas-national-medical-products-administration
Reported Sunday, Zai Lab Received Approval...
05/13/2024 06:30:58

The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, inc...

why-duolingo-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Duolingo Shares Are Trading Lower By A...
05/09/2024 17:57:05

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

spectrum-brands-posts-upbeat-results-joins-aersale-sinclair-icu-medical-and-other-big-stocks-moving-higher-on-thursday
Spectrum Brands Posts Upbeat Results, Join...
05/09/2024 14:25:23

top-5-health-care-stocks-that-could-sink-your-portfolio-in-q2
Top 5 Health Care Stocks That Could Sink Y...
05/09/2024 12:44:39

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 12:06:31

zai-lab-q1-2024-gaap-eps-055-beats-094-estimate-sales-8710m-beat-7524m-estimate
Zai Lab Q1 2024 GAAP EPS $(0.55) Beats $(0...
05/08/2024 20:19:36

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.94) by 41...

one-good-one-bad-news-for-bristol-myers-squibbs-marketed-drugs-details
One Good, One Bad News For Bristol Myers S...
04/01/2024 13:44:31

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint...

Core News & Articles
Zai Lab Shares Higher; Co Noted Partner B...
04/01/2024 11:34:31

Core News & Articles
Novocure Announces METIS Phase 3 Clinical ...
03/27/2024 13:30:21

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Field...

stock-disconnect-triggers-investor-exodus-from-cstone-pharma
Stock Disconnect Triggers Investor Exodus ...
03/14/2024 18:48:29

Key Takeaways: CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding ...

zai-lab-to-present-findings-from-preclinical-studies-highlighting-zl-1310-a-novel-antibody-drug-conjugate-adc-for-treatment-of-solid-tumors
Zai Lab To Present Findings From Preclinic...
03/14/2024 06:38:31

ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid t...

zai-lab-to-present-final-overall-survival-dataffrom-phase-3-nora-study-of-zejula-in-platinum-sensitive-recurrent-ovarian-cancer
Zai Lab To Present Final Overall Survival ...
03/06/2024 21:12:54

- Findings will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO) ...

citigroup-maintains-buy-on-zai-lab-lowers-price-target-to-66
Citigroup Maintains Buy on Zai Lab, Lowers...
02/29/2024 17:18:10

Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the price target from $123 to $66.

recap-zai-lab-q4-earnings
Recap: Zai Lab Q4 Earnings
02/27/2024 21:55:38

zai-lab-q4-2023-gaap-eps-098-misses-086-estimate-sales-6583m-miss-7346m-estimate
Zai Lab Q4 2023 GAAP EPS $(0.98) Misses $(...
02/27/2024 21:51:40

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.86) by ...

earnings-scheduled-for-february-27-2024
Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

top-5-health-care-stocks-that-are-preparing-to-pump-in-february
Top 5 Health Care Stocks That Are Preparin...
02/09/2024 13:35:36

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION